NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
NEOGEN CORP
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026
$11.63−0.18 (-1.52%)
Close on Oct 19, 2026
- Market cap
- $2.54B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$5.75 (+97.79%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
NEOGEN CORP saw revenue fall 0.3% to $883.99M over the twelve months to Aug 31, 2026. Free cash flow was $49.80M.
Revenue
$883.99M
-0.3% vs. a year earlier
Operating income
-$7.38M
TTM Q1 2027
Free cash flow
$49.80M
TTM Q1 2027
EPS, diluted
-$0.25
TTM Q1 2027
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Aug 31, 2026
Valuation
- Market cap
- $2.54B
- P/E ratio
- –
- Price to sales
- 2.87
- Price to book
- 1.22
- Dividend yield
- –
- Free cash flow yield
- 1.96%
Fundamentals
- Revenue
- $883.99M
- Net income
- -$56.12M
- EPS, diluted
- -$0.25
- Free cash flow
- $49.80M
- Book value per share
- $9.57
- Diluted shares
- 218M
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
$883.99M-0.3% YoY
Gross profit
$418.98M+1.8% YoY
Operating income
-$7.38M
Net income
-$56.12M
EPS, diluted
-$0.25
Free cash flow
$49.80M
Reported periodTrailing twelve months